<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22014" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>GABA Receptor</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Allen</surname>
            <given-names>Mary J.</given-names>
          </name>
          <aff>Lincoln Memorial University-DeBusk College of Osteopathic</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sabir</surname>
            <given-names>Sarah</given-names>
          </name>
          <aff>Rawalpindi Medical University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharma</surname>
            <given-names>Sandeep</given-names>
          </name>
          <aff>Mery Fitzgerald Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mary Allen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sarah Sabir declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sandeep Sharma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>13</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22014.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Gamma-aminobutyric acid (GABA) is an amino acid that functions as the primary inhibitory neurotransmitter for the central nervous system (CNS). It functions to reduce neuronal excitability by inhibiting nerve transmission. GABAergic neurons are located when the hippocampus, thalamus, basal ganglia, hypothalamus, and brainstem. The balance between inhibitory neuronal transmission via GABA and excitatory neuronal transmission via glutamate is essential for proper cell membrane stability and neurologic function.</p>
      </sec>
      <sec id="article-22014.s2" sec-type="Function">
        <title>Function</title>
        <p>
<bold>Synthesis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>GABA is formed from glutamate via the addition of glutamate decarboxylase and vitamin B6. GABA can then be used to form succinate, which is involved in the citric acid cycle. Once GABA is formed, is it released into the post-synaptic terminals of neurons.</p>
          </list-item>
          <list-item>
            <p>Although glutamate is a precursor for GABA, their roles are opposite in the nervous system. Glutamate is considered an excitatory neurotransmitter, while GABA is an inhibitory neurotransmitter. The imbalance of glutamate and GABA can play a role in various pathologies, as discussed in Clinical Significance.<xref ref-type="bibr" rid="article-22014.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Receptors</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>GABA receptors are receptors that respond when GABA is released into the post-synaptic nerve terminal. They are considered the chief inhibitory receptors for the central nervous system. GABA receptors are subdivided into GABAa and GABAb.&#x000a0;<xref ref-type="bibr" rid="article-22014.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>GABAa is classified as a ligand-gated ion channel/inotropic receptor. GABAa is considered in fast synaptic inhibition. Upon the receptor binding to GABA, an ion pore opens to allow chloride to move across the cell membrane. Chloride is a negatively charged ion and will follow into the area of positive charge. Typically, chloride will flow into the intracellular space. The addition of negative charge will decrease the resting potential of the cell, thus causing an inhibitory effect. GABAa receptors are located throughout the central nervous system. However, they have high concentrations in the limbic system and the retina.&#x000a0;<xref ref-type="bibr" rid="article-22014.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>GABAb receptor is a G-couple protein receptor. GABAb receptors are considered slow synaptic inhibitors. After GABA has bound to the receptor, potassium conductance is increased. Adenylyl cyclase is activated, which prevents calcium entry thus inhibits presynaptic release of other neurotransmitters. GABAb locations include the thalamic pathways and cerebral cortex.<xref ref-type="bibr" rid="article-22014.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Brain Development&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Within the adult central nervous system, GABA is the primary inhibitory neurotransmitter. However, during embryonic development, GABA acts as an excitatory neurotransmitter. GABA is thought to be the first neurotransmitter active within the developing brain and plays a role in the proliferation of neuronal progenitor cells. High levels of GABA in ventricular areas increased proliferation and neural progenitor cell size; however, in the subventricular zone, GABA decreased proliferation.&#x000a0;<xref ref-type="bibr" rid="article-22014.r4">[4]</xref>,<xref ref-type="bibr" rid="article-22014.r5">[5]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22014.s3" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Various diseases have been associated with low levels of GABA. Many psychiatric illnesses have been linked to low concentrations of GABA. Generalized anxiety is one example. As GABA is an inhibitory neurotransmitter, decreased concentration of it would produce a feeling of anxiousness. It has also been associated with schizophrenia, autism spectrum disorder, and major depressive disorder. It is important to note that although GABA concentrations may be altered in these psychiatric diseases, treatment using GABAa receptor agonists are not first-line therapy, due to high addiction potential and potentially fatal adverse effect. Valproic acid, a GABA analog, can be used for mood instability due to the enhancement of GABA concentrations.&#x000a0;<xref ref-type="bibr" rid="article-22014.r1">[1]</xref>,<xref ref-type="bibr" rid="article-22014.r6">[6]</xref></p>
        <p>Seizures and epilepsy are associated with low levels of GABA. With decreased levels of inhibition in the cerebral cortex, cells become depolarized, leading to seizure activity. GABA agonists, such as Valproic acid, are used for the treatment of seizures. Abrupt withdrawal from medications such as benzodiazepines, a GABAa positive allosteric modulator, can provoke seizures. Also, GABA antagonists are pro-convulsant.&#x000a0;<xref ref-type="bibr" rid="article-22014.r7">[7]</xref></p>
        <p>Inherited disorders of GABA metabolism are rare and therefore require an increase in clinical suspension. The most common diseases are GABA-transaminase deficiency, succinic semialdehyde dehydrogenase deficiency (SSADH), and homocarnosinosis. SSADH is the most common of neurotransmitter deficiencies. It presents with vague phenotype, varying neurological manifestations, and psychiatric illness. GABA is unable to be converted to succinic acid, and gamma-hydroxybutyrate (GHB) accumulates. Elevated concentrations of GABA and GHB are found within serum and urine. Diagnosis can be made with urinary excretion of GABA and increased signaling in the globus pallidus on MRI. Characteristics include expressive language impairment, hypotonia, and seizures. The most common neuropsychiatric problem is sleep disturbance; other issues include inattention, hyperactivity, and obsessive-compulsive disorder (OCD). There is currently no standard treatment for SSADH deficiency.&#x000a0;<xref ref-type="bibr" rid="article-22014.r8">[8]</xref></p>
        <p>GABA-transaminase deficiency and homocarnosinosis are much rarer. GABA-transaminase deficiency is an autosomal recessive disorder. Patients may have seizures presenting in the neonatal period; other manifestations include hypotonia, hyperreflexia, severely delayed psychomotor development, and a high-pitched cry. High concentrations of GABA are found in serum and cerebrospinal fluid (CSF). Cerebrospinal fluid is needed for diagnosis. Homocarnosinosis has only been reported in one family. Characteristics include progressive spastic diplegia, intellectual disability, and retinitis pigmentosa.&#x000a0;<xref ref-type="bibr" rid="article-22014.r8">[8]</xref></p>
      </sec>
      <sec id="article-22014.s4" sec-type="Other Issues">
        <title>Other Issues</title>
        <p>
<bold>Pharmacology</bold>
</p>
        <p>
<bold>
<italic toggle="yes">GABA Agonist</italic>
</bold>
</p>
        <p>Drugs that increase the amount of GABA are commonly used as anticonvulsants, sedatives, and anxiolytics. Due to the increase in GABA, CNS depression is a common adverse effect. Some GABA agonist has addiction potential, and use should be monitored closely.&#x000a0;<xref ref-type="bibr" rid="article-22014.r9">[9]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">GABAa receptor agonists:</italic> Alcohol (ethanol), barbiturates, and&#x000a0;benzodiazepine. Barbiturates include phenobarbital and sodium thiopental. Barbiturates are less frequently used due to the high addiction potential and lack of an antidote. Benzodiazepines have mainly replaced them. Benzodiazepines can treat anxiety, agitation, seizures, and muscle spasms. Only short-term use of benzodiazepine is encouraged. An overdose of benzodiazepines can be fatal due to respiratory depression, especially if concomitant use with alcohol and opioids. Flumazenil is the reversal agent for benzodiazepines.&#x000a0;<xref ref-type="bibr" rid="article-22014.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">GABAb receptor agonists:</italic> Baclofen, sodium&#x000a0;oxybate (GHB), propofol. GABAb agonists increase CNS depression. Baclofen is typically used as a muscle relaxant to treat spasticity. GHB is approved for the treatment of narcolepsy. Severe CNS depression is common is GHB. Significant respiratory depression and obtundation are commonly seen. Propofol is used for induction and maintenance of general anesthesia. Adverse effects include hypotension, apnea, and involuntary body movements.&#x000a0;<xref ref-type="bibr" rid="article-22014.r9">[9]</xref><xref ref-type="bibr" rid="article-22014.r10">[10]</xref><xref ref-type="bibr" rid="article-22014.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">GABA analogs:</italic> Valproic acid, pregabalin, gabapentin. GABA analogs are used as anticonvulsants, sedatives, and anxiolytics. As with other medications that increase GABA, CNS depression is common in this class of drugs. Valproate is prescribed for the treatment of seizures and mood instability. Pregabalin is used for fibromyalgia, diabetic neuropathy, and postherpetic neuralgia. Gabapentin&#x02019;s approved uses include postherpetic neuralgia and seizures. Off-label uses include diabetic neuropathy and fibromyalgia.&#x000a0;<xref ref-type="bibr" rid="article-22014.r9">[9]</xref></p>
          </list-item>
        </list>
        <p>
<bold>
<italic toggle="yes">GABA Antagonist</italic>
</bold>
</p>
        <p>Drugs that bind to but do not increase the amount of GABA are considered antagonists. Examples include picrotoxin or bicuculline methiodide. Both are mainly used for research. GABA antagonists are pro-convulsant and stimulants.&#x000a0;<xref ref-type="bibr" rid="article-22014.r7">[7]</xref>,<xref ref-type="bibr" rid="article-22014.r12">[12]</xref></p>
      </sec>
      <sec id="article-22014.s5" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The healthcare team, including physicians, physician assistants, nurse practitioners, nurses, and pharmacists must work together to monitor the usage of GABA receptor agonists. The time should recall that low levels of GABA are associated with seizures and precautions should be taken.</p>
      </sec>
      <sec id="article-22014.s6">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22014&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22014">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22014/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22014">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22014.s7">
        <title>References</title>
        <ref id="article-22014.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Bottiglieri</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Snead</surname>
                <given-names>OC</given-names>
              </name>
            </person-group>
            <article-title>GABA, gamma-hydroxybutyric acid, and neurological disease.</article-title>
            <source>Ann Neurol</source>
            <year>2003</year>
            <volume>54 Suppl 6</volume>
            <fpage>S3</fpage>
            <page-range>S3-12</page-range>
            <pub-id pub-id-type="pmid">12891648</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22014.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sigel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Steinmann</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Structure, function, and modulation of GABA(A) receptors.</article-title>
            <source>J Biol Chem</source>
            <year>2012</year>
            <month>Nov</month>
            <day>23</day>
            <volume>287</volume>
            <issue>48</issue>
            <fpage>40224</fpage>
            <page-range>40224-31</page-range>
            <pub-id pub-id-type="pmid">23038269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22014.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Padgett</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Slesinger</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>GABAB receptor coupling to G-proteins and ion channels.</article-title>
            <source>Adv Pharmacol</source>
            <year>2010</year>
            <volume>58</volume>
            <fpage>123</fpage>
            <page-range>123-47</page-range>
            <pub-id pub-id-type="pmid">20655481</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22014.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Kriegstein</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Defining the role of GABA in cortical development.</article-title>
            <source>J Physiol</source>
            <year>2009</year>
            <month>May</month>
            <day>01</day>
            <volume>587</volume>
            <issue>Pt 9</issue>
            <fpage>1873</fpage>
            <page-range>1873-9</page-range>
            <pub-id pub-id-type="pmid">19153158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22014.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>GABA receptors in brain development, function, and injury.</article-title>
            <source>Metab Brain Dis</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>367</fpage>
            <page-range>367-79</page-range>
            <pub-id pub-id-type="pmid">24820774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22014.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sch&#x000fc;r</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Draisma</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Wijnen</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Boks</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Koevoets</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Jo&#x000eb;ls</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klomp</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Kahn</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Vinkers</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Brain GABA levels across psychiatric disorders: A systematic literature review and meta-analysis of (1) H-MRS studies.</article-title>
            <source>Hum Brain Mapp</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>37</volume>
            <issue>9</issue>
            <fpage>3337</fpage>
            <page-range>3337-52</page-range>
            <pub-id pub-id-type="pmid">27145016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22014.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Treiman</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>GABAergic mechanisms in epilepsy.</article-title>
            <source>Epilepsia</source>
            <year>2001</year>
            <volume>42 Suppl 3</volume>
            <fpage>8</fpage>
            <page-range>8-12</page-range>
            <pub-id pub-id-type="pmid">11520315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22014.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pearl</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Hartka</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Cabalza</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Inherited disorders of GABA metabolism.</article-title>
            <source>Future Neurol</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>1</volume>
            <issue>5</issue>
            <fpage>631</fpage>
            <page-range>631-636</page-range>
            <pub-id pub-id-type="pmid">23842532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22014.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>de Haas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de Kam</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Gerven</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>An Overview of the CNS-Pharmacodynamic Profiles of Nonselective and Selective GABA Agonists.</article-title>
            <source>Adv Pharmacol Sci</source>
            <year>2012</year>
            <volume>2012</volume>
            <fpage>134523</fpage>
            <pub-id pub-id-type="pmid">22363345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22014.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cash</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Gamma-hydroxybutyrate: an overview of the pros and cons for it being a neurotransmitter and/or a useful therapeutic agent.</article-title>
            <source>Neurosci Biobehav Rev</source>
            <year>1994</year>
            <season>Summer</season>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>291</fpage>
            <page-range>291-304</page-range>
            <pub-id pub-id-type="pmid">7914688</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22014.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brohan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goudra</surname>
                <given-names>BG</given-names>
              </name>
            </person-group>
            <article-title>The Role of GABA Receptor Agonists in Anesthesia and Sedation.</article-title>
            <source>CNS Drugs</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>31</volume>
            <issue>10</issue>
            <fpage>845</fpage>
            <page-range>845-856</page-range>
            <pub-id pub-id-type="pmid">29039138</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22014.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnston</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Advantages of an antagonist: bicuculline and other GABA antagonists.</article-title>
            <source>Br J Pharmacol</source>
            <year>2013</year>
            <month>May</month>
            <volume>169</volume>
            <issue>2</issue>
            <fpage>328</fpage>
            <page-range>328-36</page-range>
            <pub-id pub-id-type="pmid">23425285</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
